USA flag logo/image

An Official Website of the United States Government

Novel epoxide hydrolase inhibitor for stroke prevention

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
76387
Program Year/Program:
2005 / STTR
Agency Tracking Number:
NS053002
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Arete Therapeutics, Inc.
3912 Trust Way Hayward, CA 94545
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2005
Title: Novel epoxide hydrolase inhibitor for stroke prevention
Agency: HHS
Contract: 1R41NS053002-01
Award Amount: $100,000.00
 

Abstract:

DESCRIPTION (provided by applicant): A major cause of morbidity and mortality is the progression of organ damage associated with cardiovascular diseases. For instance, the incidence of stroke and costs associated with stroke damage continues to have a devastating impact on public health despite numerous treatments aimed at cardiovascular risk factors. Recent findings indicate that increasing levels of epoxides of arachidonic acid (EETs) appear to be new and excellent means to treat cardiovascular diseases. We demonstrated that in vivo inhibition of soluble epoxide hydrolase (SEH) resulted in higher levels of EETs and kidney protection in animal models of hypertension. More recently, we have conducted preliminary studies that suggest that SEH inhibitors can protect the brain from cerebral ischemic damage. Therefore, we will test the hypothesis that SEH inhibitors will have stroke damage protection that is due to decreased cerebral vascular injury and platelet aggregation. First, we will evaluate the ability of a newly developed orally active SEH inhibitor to prevent stroke damage associated with cardiovascular disease. Secondly, we will determine the effect of SEH inhibition on cerebral artery structure, endothelial function and platelet function in stroke-prone spontaneously hypertensive (SHRSP) rats. In the Phase II work, Arete Therapeutics will use the collected information to progress toward clinical trials in the area of stroke and possible new therapeutic avenues.

Principal Investigator:

John D. Imig
7067211901
JDIMIG@MCG.EDU

Business Contact:


5107857060
Small Business Information at Submission:

Arete Therapeutics, Inc.
3912 Trust Way Hayward, CA 94545

EIN/Tax ID: 680572963
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
MEDICAL COLLEGE OF GEORGIA
MEDICAL COLLEGE OF GEORGIA (MCG)
1120 15TH ST
AUGUSTA, GA 30912
RI Type: Nonprofit college or university